Meeting
2023 ASCO Annual Meeting
Prognostic impact of depth of response (DpR) and early tumour shrinkage (ETS) in patients (pts) with BRAF V600E mutated (mut) metastatic colorectal cancer (mCRC) receiving targeted therapy (TT) as second-line treatment.
Authors
Guglielmo Vetere
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
Guglielmo Vetere , Marco Maria Germani , Maria Bensi , Carlotta Antoniotti , Sara Lonardi , Alessandro Passardi , Filippo Ghelardi , Maria Alessandra Calegari , Beatrice Borelli , Sara Santucci , Rossana Intini , Eleonora Cristarella , Mara Persano , Alberto Puccini , Daniele Lavacchi , Laura Noto , Clizia Zichi , Riccardo Giampieri , Massimiliano Salati , Chiara Cremolini
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3568)
DOI
10.1200/JCO.2023.41.16_suppl.3568
Abstract #
3568
Poster Bd #
268
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2019 Gastrointestinal Cancers Symposium
Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Retrospective analysis of adherence and persistence of encorafenib in combination with cetuximab among patients with BRAF metastatic CRC in the United States (US).
First Author: Aparna Raj Parikh
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Retrospective analysis of the real-world demographics, clinical characteristics, and treatment patterns in metastatic CRC among patients treated with encorafenib in combination with cetuximab in the United States.
First Author: Aparna Raj Parikh